BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 15877069)

  • 1. Therapeutic antibody gene transfer.
    Marasco WA
    Nat Biotechnol; 2005 May; 23(5):551-2. PubMed ID: 15877069
    [No Abstract]   [Full Text] [Related]  

  • 2. Stable antibody expression at therapeutic levels using the 2A peptide.
    Fang J; Qian JJ; Yi S; Harding TC; Tu GH; VanRoey M; Jooss K
    Nat Biotechnol; 2005 May; 23(5):584-90. PubMed ID: 15834403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering mouse monoclonal antibodies for cancer immunotherapy.
    Orlandi R
    Year Immunol; 1993; 7():69-73. PubMed ID: 8372514
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapeutic antibodies: magic bullets hit the target.
    Gura T
    Nature; 2002 Jun; 417(6889):584-6. PubMed ID: 12050630
    [No Abstract]   [Full Text] [Related]  

  • 5. Recombinant chimeric monoclonal antibodies.
    Morrison SL; Schlom J
    Important Adv Oncol; 1990; ():3-18. PubMed ID: 2182522
    [No Abstract]   [Full Text] [Related]  

  • 6. Tunable antibodies.
    Weiner LM; Carter P
    Nat Biotechnol; 2005 May; 23(5):556-7. PubMed ID: 15877072
    [No Abstract]   [Full Text] [Related]  

  • 7. Development of humanized antibodies as cancer therapeutics.
    Qu Z; Griffiths GL; Wegener WA; Chang CH; Govindan SV; Horak ID; Hansen HJ; Goldenberg DM
    Methods; 2005 May; 36(1):84-95. PubMed ID: 15848077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic re-targeting of T lymphocyte specificity.
    Bolhuis RL; Gratama JW
    Gene Ther; 1998 Sep; 5(9):1153-5. PubMed ID: 9930314
    [No Abstract]   [Full Text] [Related]  

  • 9. Designer mice: the production of human antibody repertoires in transgenic animals.
    Brüggemann M; Davies NP; Rosewell IR
    Year Immunol; 1993; 7():33-40. PubMed ID: 8372511
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor.
    Lin J; Lalani AS; Harding TC; Gonzalez M; Wu WW; Luan B; Tu GH; Koprivnikar K; VanRoey MJ; He Y; Alitalo K; Jooss K
    Cancer Res; 2005 Aug; 65(15):6901-9. PubMed ID: 16061674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective gene transfer into neurons via Na,K-ATPase beta1. Targeting gene transfer with monoclonal antibody and adenovirus vector.
    Ishii K; Nakamura K; Kawaguchi S; Li R; Hirai S; Sakuragi N; Wada T; Kato K; Yamashita T; Hamada H
    J Gene Med; 2008 Jun; 10(6):597-609. PubMed ID: 18383483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy.
    Zhang Q; Chen G; Liu X; Qian Q
    Cell Res; 2007 Feb; 17(2):89-99. PubMed ID: 17242688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic antibodies and antibody fusion proteins.
    Rohrbach P; Broders O; Toleikis L; Dübel S
    Biotechnol Genet Eng Rev; 2003; 20():137-63. PubMed ID: 14997850
    [No Abstract]   [Full Text] [Related]  

  • 14. Generation and selection of targeted adenoviruses embodying optimized vector properties.
    Noureddini SC; Krendelshchikov A; Simonenko V; Hedley SJ; Douglas JT; Curiel DT; Korokhov N
    Virus Res; 2006 Mar; 116(1-2):185-95. PubMed ID: 16293334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of engineered antibodies.
    Hwang WY; Foote J
    Methods; 2005 May; 36(1):3-10. PubMed ID: 15848070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies and gene therapy: teaching old 'magic bullets' new tricks.
    Sanz L; Blanco B; Alvarez-Vallina L
    Trends Immunol; 2004 Feb; 25(2):85-91. PubMed ID: 15102367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viral or non-viral angiogenesis gene transfer-New answers to old questions.
    Nikol S
    Cardiovasc Res; 2007 Feb; 73(3):443-5. PubMed ID: 17196566
    [No Abstract]   [Full Text] [Related]  

  • 18. Tailor-made antibody therapeutics.
    Chowdhury PS; Wu H
    Methods; 2005 May; 36(1):11-24. PubMed ID: 15848071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FasL gene therapy: a new therapeutic modality for head and neck cancer.
    ElOjeimy S; McKillop JC; El-Zawahry AM; Holman DH; Liu X; Schwartz DA; Day TA; Dong JY; Norris JS
    Cancer Gene Ther; 2006 Aug; 13(8):739-45. PubMed ID: 16543918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant fusion proteins TAT-Mu, Mu and Mu-Mu mediate efficient non-viral gene delivery.
    Rajagopalan R; Xavier J; Rangaraj N; Rao NM; Gopal V
    J Gene Med; 2007 Apr; 9(4):275-86. PubMed ID: 17397090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.